Table 3.
Variable |
Entire cohort
n = 893 (100%) |
Stage I1
n = 228 (25.5%) |
Stage II1
n = 444 (49.7%) |
Stage IIIA1
n = 221 (24.7%) |
||||
HR (95%CI) | aP | HR (95%CI) | bP | HR (95%CI) | cP | HR (95%CI) | dP | |
Age, yr | 1.001 (1.000-1.002) | 0.504 | 1.001 (1.000-1.002) | 0.934 | 1.001 (1.000-1.002) | 0.449 | 1.001 (1.000-1.002) | 0.057 |
Sex | ||||||||
Male | 1 | 1 | 1 | 1 | ||||
Female | 0.684 (0.532-0.879) | 0.003 | 0.317 (0.156-0.645) | 0.002 | 0.553 (0.346-0.881) | 0.013 | 0.494 (0.299-0.818) | 0.006 |
Race | ||||||||
White | 1 | 1 | 1 | 1 | ||||
Black | 1.475 (1.008-2.160) | 0.046 | 4.593 (1.625-12.981) | 0.004 | 1.645 (0.775-3.490) | 0.195 | 2.245 (0.904-5.575) | 0.082 |
Others | 0.821 (0.551-1.224) | 0.334 | 0.262 (1.975) | 0.719 | 0.509 (0.245-1.056) | 0.070 | 1.362 (0.609-3.047) | 0.452 |
Grade1 | ||||||||
Well | 1 | 1 | 1 | 1 | ||||
Moderate | 0.840 (0.609-1.157) | 0.286 | 0.418 (0.194-0.902) | 0.026 | 1.568 (0.905-2.715) | 0.109 | 0.297 (0.125-0.704) | 0.006 |
Poor | 1.291 (0.908-1.835) | 0.155 | 1.339 (0.449-3.994) | 0.601 | 2.412 (1.306-4.453) | 0.005 | 0.629 (0.259-1.531) | 0.307 |
Undifferentiated | 2.101 (0.891-4.954) | 0.090 | / | / | 4.059 (1.033-15.951) | 0.045 | 1.434 (0.323-6.373) | 0.636 |
Unknown | 0.856 (0.503-1.455) | 0.565 | 0.384 (0.134-1.106) | 0.076 | 2.376 (0.857-6.583) | 0.096 | 0.260 (0.068-1.003) | 0.050 |
Radiation | ||||||||
No | 1 | 1 | 1 | 1 | ||||
Yes | 0.727 (0.515-1.027) | 0.071 | 1.055 (0.302-3.688) | 0.933 | 0.781 (0.430-1.419) | 0.417 | 0.390 (0.215-0.708) | 0.002 |
No. of LNs examined | 1.001 (1.000-1.002) | 0.162 | 1.001 (1.000-1.002) | 0.910 | 1.001 (1.000-1.002) | 0.382 | 1.001 (1.000-1.002) | 0.167 |
Stage1 | ||||||||
I | 1 | / | / | / | / | / | / | |
II | 1.089 (0.793-1.497) | 0.598 | / | / | / | / | / | / |
IIIA | 3.730 (2.635-5.280) | 0.000 | / | / | / | / | / | / |
AJCC/TNM 8th edition. OS: Overall survival.